Recursion raises $239M in Series D, partners with lead investor Bayer
The partnership includes a $30 million upfront payment from Bayer and potentially more than $100 million in milestones per program generated through the partnering of the German drugmaker's molecule library and Recursion's artificial intelligence-based drug discovery platform.